Hyperkalemia in Tumor Lysis Syndrome

Pathophysiology and Clinical Manifestations

• The rapid lysis of tumor cells releases massive amounts of intracellular potassium into the bloodstream, which is further exacerbated by concurrent renal failure that impairs potassium excretion, according to the American Society of Clinical Oncology 1, 2
• Elevated potassium levels produce cardiac irregularities including arrhythmias, ventricular tachycardia, and fibrillation, which manifest clinically as palpitations, as reported by the American Society of Clinical Oncology 1, 2
• High potassium levels also cause neuromuscular effects including muscle cramps and paresthesias, explaining the muscle aches in patients with tumor lysis syndrome, as noted by the American Society of Clinical Oncology 1, 2
• Nausea and vomiting are part of the general clinical manifestations of tumor lysis syndrome that can occur with multiple electrolyte abnormalities, but when combined with palpitations and muscle aches, they point specifically to hyperkalemia, according to the American Society of Clinical Oncology 2, 3

Clinical Significance and Mortality Risk

• Clinical tumor lysis syndrome with significant hyperkalemia carries a high mortality rate, with an 83% mortality rate compared to 24% in patients without clinical tumor lysis syndrome, as reported by the American Society of Clinical Oncology 4
• In a cohort of patients with Burkitt's lymphoma, two of four deaths were directly attributable to hyperkalemia, underscoring its life-threatening nature, according to the American Society of Clinical Oncology 4, 5

Immediate Management Priorities

• For severe hyperkalemia, treatment includes rapid insulin (0.1 units/kg) plus glucose (25% dextrose 2 mL/kg) to shift potassium intracellularly, as recommended by the European Hematology Association 6
• Calcium carbonate (100-200 mg/kg/dose) stabilizes myocardial cell membranes and prevents life-threatening arrhythmias, according to the European Hematology Association 6
• Emergency hemodialysis is indicated for persistent or life-threatening hyperkalemia unresponsive to medical management, as recommended by the European Hematology Association 6, 7

Hyperkalemia in Tumor Lysis Syndrome: Pathophysiology, Clinical Features, and Management

Pathophysiology

• The rapid lysis of tumor cells releases large amounts of intracellular potassium into the bloodstream, and concurrent renal failure further impairs potassium excretion, leading to marked hyperkalemia. 8

Clinical Manifestations Attributable to Hyperkalemia

• Palpitations arise from cardiac electrical disturbances—including arrhythmias, ventricular tachycardia, and fibrillation—that are precipitated by elevated serum potassium levels. 8
• Muscle weakness and cramps represent neuromuscular effects of high potassium concentrations. 8

Differential Diagnosis: Other Electrolyte Abnormalities in TLS

• Hypocalcemia more commonly produces tetany and seizures rather than the palpitations and muscle weakness seen with hyperkalemia. 9
• Hyperuricemia primarily causes renal complications (oliguria and acute renal failure) through crystal deposition and does not generate the cardiac or neuromuscular symptoms characteristic of hyperkalemia. 8
• Hypomagnesemia is not a cardinal feature of tumor lysis syndrome. 8

Management of Severe Hyperkalemia (≥6 mmol/L)

• Immediate therapy includes rapid intravenous insulin (0.1 U/kg) combined with 25 % dextrose (2 mL/kg) to shift potassium intracellularly, administration of calcium carbonate (100–200 mg/kg per dose) to stabilize myocardial membranes, and continuous ECG monitoring. 10

Hyperkalemia Management in Tumor Lysis Syndrome

Pathophysiology and Clinical Presentation

• Elevated serum potassium in tumor lysis syndrome precipitates cardiac electrical disturbances (arrhythmias, ventricular tachycardia, fibrillation) that manifest as palpitations. 11
• High potassium concentrations cause neuromuscular dysfunction, presenting as generalized muscle weakness, cramps, and body aches. 11

Differential Diagnosis

• In tumor lysis syndrome, hypocalcemia typically produces neuromuscular irritability (tetany, seizures, carpopedal spasm, positive Chvostek/Trousseau signs) rather than palpitations or muscle weakness. 12
• Hyperuricemia in tumor lysis syndrome leads primarily to renal complications (oliguria, acute renal failure from uric acid crystal deposition) and does not generate cardiac or neuromuscular symptoms such as palpitations or weakness. 11
• Hypomagnesemia is not a defining feature of tumor lysis syndrome; the syndrome is characterized by hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia. [12][11]

Immediate Management

• Initiate continuous electrocardiographic monitoring in any patient with suspected hyperkalemia to detect life‑threatening arrhythmias promptly. [12][13]
• For severe hyperkalemia (serum potassium ≥ 6 mmol/L), administer rapid intravenous insulin (0.1 U/kg) together with 25 % dextrose (2 mL/kg) to drive potassium intracellularly. [12][13]
• Give calcium carbonate (100–200 mg/kg as a single dose) to stabilize myocardial cell membranes and reduce the risk of ventricular fibrillation or cardiac arrest. [12][13]
• Prepare for emergency hemodialysis when hyperkalemia persists despite medical therapy or when the patient is hemodynamically unstable, as dialysis rapidly lowers plasma potassium and can be lifesaving. [12][13]

Critical Clinical Pitfall

• Do not await laboratory confirmation of serum potassium when the clinical picture (palpitations plus muscle weakness in a tumor lysis context) strongly suggests hyperkalemia; initiate empiric treatment immediately to avoid fatal delays.

All facts are derived from peer‑reviewed sources cited above; no patient‑identifiable information is included.